
THE WAS THE THE WAS THE WAS THE WAY TH

====

TOP TO THE



"Express Mail" mailing label number EL 315 815 124 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 12-10-99

By: Many Kama

Printed: Nancy Ramos



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE REQUEST FOR FILING A PATENT APPLICATION UNDER 37 CFR 1.53(b)

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Dear Sir:

This is a request for filing a **DIVISIONAL** application under 37 CFR 1.53(b) of pending prior application Serial No. 09/196,480, filed on November 19, 1998, which is a divisional application of U.S. application Serial No. 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393, both entitled A NOVEL HUMAN JAK2 KINASE.

- 1. X Enclosed is a copy of the prior application, U.S. Application Serial No. 08/567,508 filed December 5, 1995, including the oath or declaration as originally signed.
- 2. X With regard to the requirement of 37 CFR 1.821(e) which requires that a copy of the Sequence Listing in computer readable form (CRF) be submitted, Applicants state that the computer readable form of the "Sequence Listing" for the instant divisional application is identical with the substitute sequence listing filed December 11, 1997, for Serial No. 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393, to which priority is claimed. In accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed with the December 11, 1997 substitute sequence listing, as the computer readable form for the instant divisional application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant divisional application.
- 3. X Cancel in this application original claims 2, 3, and 11-13 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- 4. X The inventors of the invention being claimed in this application are: Roger Coleman and Susan G. Stuart.

- 5. X In accordance with 37 CFR 1.63(d), a copy of the originally signed declaration showing applicants' signatures as filed on March 20, 1996 is enclosed.
- 6. X Amend the specification by inserting before the first line the sentence: "This application is a divisional application of U.S. application serial number 09/196,480, filed November 19, 1998, which is a divisional of U.S. application serial number 08/567,508, filed December 5, 1995, issued June 22, 1999, as U.S. Patent No. 5,914,393."
- 7. X The filing fee is calculated below:

Claims	Number Filed	Minus	Number Extra	Other Than Small Entity		Basic Fee
				Rate	Fee	\$760,00
Total Claims	13	-20	0	x \$18		\$0
Indep. Claims	1	-3	0	x \$78		\$ 0
Multiple Dependent Claim(s), if any + \$260						\$0


TOTAL FILING FEE \$ 760.00

- 8. ___ An extension of time in the above-named prior application has been requested and the fees therefore have been authorized in said application.
- 9. X Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. <u>09-0108</u> in the amount of \$760.00.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Incyte Pharmaceuticals, Inc. Account No. **09-0108**.

A duplicate copy of this Request is enclosed.

- 10. X New formal drawings are enclosed.
- 11. X The prior application is assigned of record to <u>Incyte Pharmaceuticals</u>, <u>Inc</u>, recorded on March 25, 1996, at reel 7984/frame 0461.
- 12. X A preliminary amendment is enclosed.
- 13. X Also enclosed Return Postcard, Information Disclosure Statement, List of Cited References (1449), copy of previously submitted Certificate, Revocation of Power of Attorney and Appointment of New Attorneys, Submission of Formal Drawings, copy of Substitute Submission Under 37 C.F.R. 1.821-1.825, and copy of previously submitted Substitute Sequence Listing.



- a. ___ An associate power of attorney is attached.
- b. ___ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. X Address all future correspondence to:

INCYTE PHARMACEUTICALS, INC. PATENT DEPARTMENT 3174 Porter Drive

Palo Alto, California 94304 Phone: (650) 855-0555, Fax: (650) 849-8886

Date: Occember 9,1999

By:

Susan K. Nather

Susan K. Sather Reg. No. 44,316

Direct Dial Telephone: (650) 845-4646

	Inventor(s)
	Assignee of complete interest
<u>X</u>	_Attorney or agent of record
_	Filed under 37 CFR 1.34(a)
	Registration number if acting under 37 CFR 1 34(a)



ocket No.: PF-0049-2 DIV

"Express Mail" mailing label number EL 315 815 124 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 12 - 10 - 99

By: Many Ramos

Printed: Nancy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman and Stuart

Title:

A NOVEL HUMAN JAK2 KINASE

Serial No.:

To Be Assigned

Filing Date:

Herewith

Examiner:

To Be Assigned

Group Art Unit:

To Be Assigned

Official Draftsman

Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231

SUBMISSION OF FORMAL DRAWINGS


Sir:

Transmitted herewith are Figures 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, as thirteen (13) sheets of formal drawings for this application. Each sheet of drawing indicates the identifying indicia suggested in 37 CFR Section 1.84(c) on the reverse side of the drawings.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. A duplicate copy of this communication is enclosed.

50775





If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: December 9, 1999

Susan K. Nather

Susan K. Sather Reg. No. 44,316

Direct Dial Telephone: (650) 845-4646

3174 Porter Drive Palo Alto, California 94304

Phone: (650) 855-0555 Fax: (650) 849-8886

50775